Enzymatica's new rights issue completed - will be provided with SEK 60 million
in or into the United States, Australia, Japan, Canada, Hong Kong, New Zealand,
Singapore or South Africa or any other jurisdiction where such action is subject
to legal restrictions.
This press release may not be published or distributed, directly or indirectly, in or into the United States, Australia, Japan, Canada, Hong Kong, New Zealand, Singapore or South Africa or any other jurisdiction where such action is subject to legal restrictions.
The subscription period for Enzymatica AB (publ)'s ("Enzymatica" or the "Company") rights issue with preferential rights for the Company's shareholders ended on 6 May 2016 and the final result shows that approximately 56 per cent of the rights issue was subscribed for through preferential rights and that applications for subscription without preferential rights corresponding to approximately 10 per cent of the rights issue have been made. The remaining 34 per cent have been subscribed for by underwriters. The Company will be provided with approximately SEK 60 million before costs associated with the rights issue.
|-||We are very satisfied with the result of the new rights issue and particularly of the interest to subscribe by shareholders, management, board of directors and new long-term strategic investors. We will now have the possibility to run the company according to our long-term strategy with international expansion, says Fredrik Lindberg, CEO of Enzymatica.|
The final result of Enzymatica's rights issue shows that approximately 15.3 million shares, corresponding to approximately 56 per cent of the offered shares, were subscribed for through preferential rights. In addition, applications for subscription of approximately 2.8 million shares, corresponding to approximately 10 per cent of the offered shares, without preferential rights have been made.
The remaining part of the rights issue, which amounts to approximately 9.4 million shares and corresponds to approximately 34 per cent of the offered shares, have been subscribed for by underwriters who have undertaken to subscribe for and pay for any part of the rights issue not subscribed for with or without preferential rights.
Those who have subscribed for shares without preferential rights will be allocated shares in accordance with the principles set out in the prospectus published on 20 April 2016. Notices will be distributed to those who have subscribed for shares without preferential rights shortly.
Through the rights issue, Enzymatica will be provided with approximately SEK 60 million before costs associated with the rights issue. The Company's share capital will increase with approximately SEK 1,100,817.48 to approximately SEK 2,935,513.27 and the total number of shares and votes will increase with 27,520,428 to 73,387,808 shares and votes when the rights issue has been registered with the Swedish Companies Registration Office (Sw. Bolagsverket).
The new shares are estimated to be eligible for trading at NASDAQ First North as of May 25, 2016.
ABG Sundal Collier is financial advisor and Setterwalls Advokatbyrå is legal advisor to Enzymatica in relation to the new issue with preemptive rights for existing shareholders.
For more information, please contact:
Fredrik Lindberg, CEO Enzymatica AB
Tel: +46 708-86 53 70 | E-post: email@example.com
About Enzymatica AB
Enzymatica is a life science company who develops and sells medical device products against infectious-related diseases. Over a short period the company has developed a unique oral spray for colds, ColdZyme®, and launched it on six markets. The product has become one of the leading articles for colds in Swedish pharmacies. Enzymatica's strategy is to continue growing by strengthening its position in existing markets and to expand to more geographical markets through well-established partners. The company is headquartered in Lund, Sweden and is listed on Nasdaq First North. For more information, please visit www.enzymatica.com.
Enzymatica's certified advisor is Erik Penser Bankaktiebolag.
The information in this press release does not contain or constitute an offer to acquire, subscribe or otherwise trade in shares, subscription rights or other securities in Enzymatica AB (publ).
This press release may not be published or distributed, directly or indirectly in or into the United States, Australia, Japan, Canada, Hong Kong, New Zeeland, Singapore or South Africa or any other jurisdiction where such action is wholly or partially subject to legal restrictions or where such action would require additional prospectuses, registrations or other actions in addition to what follows from Swedish law. Nor may the information in this press release be forwarded, reproduced or disclosed in such a manner that contravenes such restrictions or would require such requirements. Failure to comply with this instruction may result in a violation of applicable securities laws.
No subscription rights, interim shares or new shares have been registered, and will not be registered, under the United States Securities Act of 1933 ("Securities Act") or securities legislation in any other state or other jurisdiction in the United States and may not be offered, subscribed, sold or transferred, directly or indirectly within the United States, other than pursuant to an exemption from the registration requirements of the Securities Act and in accordance with securities laws in relevant state or other jurisdiction in the United States.
This press release may contain forward-looking statements which reflect Enzymatica AB (publ):s current view on future events and financial and operational development. Words such as "intend", "expect", "anticipate", "may", "believe", "plan", "estimate" and other expressions which imply indications or predictions of future development or trends, and which are not based on historical facts, are intended to identify forward-looking statements. Forward-looking statements inherently involve both known and unknown risks and uncertainties because they depend on future events and circumstances. Forward-looking statements do not guarantee future results or development and the real outcome could differ materially from the forward-looking statements.